Updated:
Panacea Venture Healthcare Fund GP I, L.P.
Panacea Venture is a healthcare-focused venture capital firm founded by James Huang in 2017, investing in digital health and biotech across the US and...
Panacea Venture Healthcare Fund GP I, L.P.
Panacea Venture Healthcare Fund GP I, L.P. was established in 2017 by James Huang, a former executive at OrbiMed and Lilly Asia Ventures. The firm operates as a healthcare-focused venture capital fund, investing across the US and China. Huang's background in healthcare investing shapes the fund's emphasis on therapeutic and diagnostic innovations. The fund pursues early-stage opportunities in digital health, biotechnology, medical devices, and diagnostics. Portfolio companies include Guardant Health (a liquid biopsy leader), Burning Rock Biotech (cancer genomics), and other precision medicine developers. Panacea Venture typically leads or co-leads Series A and B rounds, taking board seats. The firm claims a hybrid model: sourcing US technology while leveraging China's clinical trial and manufacturing infrastructure (per public record, 2024). Panacea Venture maintains offices in Shanghai and San Francisco. The team is lean, with fewer than 15 investment professionals. Affiliated entities include Panacea Venture Capital Management Co., Ltd. and Panacea Venture Healthcare Fund II. In 2024, the firm closed its second fund at an undisclosed size, continuing its focus on cross-border healthcare deals (per public record, 2024). The fund's structural differentiator is its cross-border thesis: investing in US technology companies that can expand into China's healthcare market. This approach requires navigating regulatory and intellectual-property challenges, which Panacea Venture addresses through local partnerships and a dual-office structure.
General information
Firm type
Venture Capital
Year founded
2017
AUM
Undisclosed (Altss estimate: under $500M USD)
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
San Francisco, California, United States
Principals
James Huang
Founder & Managing Partner
Kai Li
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Panacea Venture?
James Huang is the founder and managing partner, leading investment decisions. Kai Li serves as a partner. The firm's lean team means Huang is directly involved in deal sourcing and portfolio management (per public record).
How does Panacea Venture source proprietary deal flow?
The firm leverages its dual-office network in Shanghai and San Francisco to source healthcare startups in both markets. It also maintains relationships with academic institutions and clinical research organizations to identify emerging technologies (per public record).
Is Panacea Venture structured as a single family office or does it operate more like a venture firm?
Panacea Venture operates as a venture capital fund, not a family office. It raises capital from institutional investors and high-net-worth individuals, and its structure is that of a limited partnership with general partner control (as disclosed by the firm).
What investment stages does Panacea Venture typically target?
The firm focuses on early-stage opportunities, typically leading or co-leading Series A and B rounds. Its investments span digital health, biotech, and medical devices (per public record).
Which sectors does Panacea Venture explicitly avoid?
The firm does not invest in late-stage or buyout deals, nor does it participate in non-healthcare sectors. Its mandate is exclusively healthcare-related (per public record).
How does Panacea Venture's cross-border approach differ from other healthcare VCs?
Panacea Venture invests in US technology companies with the aim of expanding into China's healthcare market. This requires navigating regulatory approvals and IP challenges, which the firm addresses through local partnerships. Most healthcare VCs focus on a single region (per public record).
Who are Panacea Venture's known portfolio companies?
Publicly known holdings include Guardant Health, a liquid biopsy company, and Burning Rock Biotech, a cancer genomics firm. Other investments are in precision medicine and diagnostics (per public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: